GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (LTS:0RDU) » Definitions » Institutional Ownership

Grifols (LTS:0RDU) Institutional Ownership : 16.47% (As of Dec. 13, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Grifols Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Grifols's institutional ownership is 16.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Grifols's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Grifols's Float Percentage Of Total Shares Outstanding is 61.96%.


Grifols Institutional Ownership Historical Data

The historical data trend for Grifols's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Institutional Ownership Chart

Grifols Historical Data

The historical data trend for Grifols can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 20.17 18.08 17.19 17.21 17.38 16.96 17.11 16.71 16.59 16.47

Grifols Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Grifols Business Description

Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Grifols Headlines

No Headlines